Moreover, we found cut-off values for NT-proBNP that will aid in the screening of patients with NET, thereby increasing focus on patients at high risk of developing CHD, and releasing patients with a low risk of CHD from burdening screening. This evidence concerns the gene NPPB and coronary artery disorder.